Date: 2015-09-22
Type of information: IPO
Company: RegenXBio (USA - MD)
Investors:
Amount: $159.4 million
Funding type: IPO
Planned used:
Others: * On September 22, 2015, RegenXBio, a leading biotechnology company in gene therapy, announced the closing of its initial public offering of 7,245,000 shares of common stock at a public offering price of $22.00 per share, which includes 945,000 shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. The gross proceeds from the initial public offering to RegenXBio were approximately $159.4 million, before underwriting discounts and estimated offering expenses. * On September 16, 2015, RegenXBio announced the pricing of its initial public offering of 6,300,000 shares of its common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions. In addition, RegenXBio granted the underwriters a 30-day option to purchase up to an additional 945,000 shares of its common stock at the same price. The shares are scheduled to begin trading on The NASDAQ Global Select Market on September 17, 2015 under the ticker symbol \"RGNX.\" Morgan Stanley and BofA Merrill Lynch are acting as active joint book-running managers of the proposed offering. Piper Jaffray is acting as a passive book-running manager. Chardan Capital Markets is acting as a co-manager. This offering will be made only by means of a prospectus.
Therapeutic area: Rare diseases - Genetic diseases
